First PREMIER Bank Sells 377 Shares of GSK plc (NYSE:GSK)

First PREMIER Bank decreased its holdings in GSK plc (NYSE:GSK) by 6.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,225 shares of the pharmaceutical company’s stock after selling 377 shares during the quarter. First PREMIER Bank’s holdings in GSK were worth $224,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Fisher Asset Management LLC lifted its holdings in shares of GSK by 10.8% in the fourth quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock valued at $558,330,000 after purchasing an additional 1,465,165 shares in the last quarter. Primecap Management Co. CA boosted its holdings in GSK by 0.3% during the 4th quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock worth $448,032,000 after acquiring an additional 30,600 shares during the last quarter. Royal Bank of Canada grew its stake in shares of GSK by 5.1% in the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock worth $292,896,000 after acquiring an additional 389,871 shares in the last quarter. Morgan Stanley raised its holdings in shares of GSK by 2.1% in the third quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock valued at $273,744,000 after purchasing an additional 156,480 shares during the last quarter. Finally, Provident Trust Co. lifted its position in shares of GSK by 53.6% during the fourth quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock valued at $137,746,000 after purchasing an additional 1,297,385 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Up 0.2 %

Shares of GSK stock opened at $40.55 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15. The firm has a market cap of $84.04 billion, a P/E ratio of 14.69, a PEG ratio of 1.22 and a beta of 0.66. The company has a 50 day moving average of $42.56 and a 200-day moving average of $41.16. GSK plc has a 12-month low of $33.67 and a 12-month high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.15. GSK had a return on equity of 51.54% and a net margin of 14.62%. The firm had revenue of $9.34 billion for the quarter, compared to analyst estimates of $8.98 billion. Sell-side analysts anticipate that GSK plc will post 4.11 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This represents a $1.50 dividend on an annualized basis and a yield of 3.71%. The ex-dividend date of this dividend is Thursday, May 16th. This is a positive change from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is currently 53.26%.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of recent analyst reports. Berenberg Bank raised shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, The Goldman Sachs Group started coverage on GSK in a research report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $47.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.